- Disease Modeling
Stem Cell Research
NEXEL Co., Ltd. is making disease modeling iPSC line by gene editing methods.
By using our advanced differentiation methods, we can generate tissue specific cells which have disease phenotypes. These cells can be used for drug screening and studying disease mechanisms.
NEXEL Co., Ltd is developing CDMO service. NEXEL’s CDMO service will be able to provide uniquely focused cell solutions in the iPSC field and cover customized solutions from research-grade to clinical projects. A decade of experience in stem cell differentiation, in-depth quality assurance systems, global partnership and project experiences enables us to develop our expertise in various types of iPSC-derived cell lines and meet the need of the global iPSC industry. We are passionate about establishing a platform where we co-develop and manufacture iPSC-based cell products for our users in the near future.